


Listing of Claims

STEVEN J. SARUSSI

312-913-0001

This listing of claims will replace all prior versions and listings of claims in the application.

(72 IS CANCELLED!)

Claims 1-187 (cancelled)Claim 188 (new) A compound of the formula

or a pharmaceutically acceptable salt thereof wherein
 R₁ is:

(I) C₁-C₆ alkyl, unsubstituted or substituted with one, two or three C₁-C₃ alkyl, -F, -Cl, -Br, -I, -OH, -NH₂, -C≡N, -CF₃, or -N₃,

(II) -(CH₂)₁₋₂-S-CH₃,

(III) -CH₂-CH₂-S-CH₃,

(IV) -CH₂-(C₂-C₆ alkenyl) unsubstituted or substituted by one -F,

(V) -(CH₂)₀₋₃-(R₁-aryl) where R₁-aryl is phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, tetralinyl unsubstituted or independently substituted on the aryl ring with one or two of C₁-C₃ alkyl, -CF₃, -F, Cl, -Br, -I, C₁-C₃ alkoxy, -O-CF₃, -NH₂, -OH, or -C≡N;

R₂ is:

(I) -H,

(II) C₁-C₆ alkyl, or

(III) $-(CH_2)_{0-4}-R_{2-1}$ where R_{2-1} is (C_3-C_6) cycloalkyl, R_{1-aryl} where R_{1-aryl} is optionally substituted with R_{100} , where R_{100} is

- (1) C_1-C_6 alkyl,
- (2) -F, -Cl, -Br, or -I,
- (3) -OH,
- (4) $-NO_2$,
- (5) -CO-OH,
- (6) -C≡N,
- (7) $-CO-NR_{8-2}R_{8-3}$ where R_{8-2} and R_{8-3} are the same or different and are:
 - (a) -H,
 - (b) $-C_1-C_6$ alkyl unsubstituted or substituted with one -OH or $-NH_2$,
 - (c) $-C_1-C_6$ alkyl unsubstituted or substituted with one to three -F, -Cl, -Br, or -I,
 - (d) $-C_3-C_7$ cycloalkyl,
 - (e) $-(C_1-C_2$ alkyl) $-(C_3-C_7$ cycloalkyl),
 - (f) $-(C_1-C_6$ alkyl) $-O-(C_1-C_3$ alkyl),
 - (g) $-C_1-C_6$ alkenyl with one or two double bonds,
 - (h) $-C_1-C_6$ alkynyl with one or two triple bonds,
 - (i) $-C_1-C_6$ alkyl chain with one double bond and one triple bond,
 - (j) $-CO-(C_3-C_{12}$ alkyl),
 - (k) $-CO-(C_3-C_6$ cycloalkyl),
 - (l) $-CO-R_{1-heterocycle}$ where $R_{1-heterocycle}$ is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyrananyl, piperidinyl, tetrahydrofurananyl, or tetrahydrothiophenyl,

where the R_1 -heterocycle group is bonded by any atom of the parent R_1 -heterocycle group substituted by hydrogen such that the new bond to the R_1 -heteroaryl group replaces the hydrogen atom and its bond, where heterocycle is unsubstituted or substituted with one or two

=O, C_1 - C_3 alkyl, - CF_3 , -F, Cl, -Br, -I, C_1 - C_3 alkoxy, - OCF_3 , - NH_2 , -OH, or - $C\equiv N$,

(12) - $CO-R_{N-4}$ where R_{N-4} is morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl where each group is unsubstituted or substituted with one or two C_1 - C_3 alkyl,

(13) - $CO-O-R_{N-5}$ where R_{N-5} is:

(a) C_1 - C_6 alkyl, or

(b) - $(CH_2)_{0-2}-(R_1\text{-aryl})$ where $R_1\text{-aryl}$ is as defined above,

(14) - $SO_2-NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} are as defined above,

(15) - $SO-(C_1-C_6$ alkyl),

(16) - $SO_2-(C_3-C_1$ alkyl),

(17) - $NH-CO-O-R_{N-5}$ where R_{N-5} is as defined above,

(18) - $NH-CO-N(C_1-C_3$ alkyl)₂,

(19) - $N-CS-N(C_1-C_3$ alkyl)₂,

(20) - $N(C_1-C_3$ alkyl)- $CO-R_{N-5}$ where R_{N-5} is as defined above,

(21) - $NR_{N-2}R_{N-3}$ where R_{N-2} and R_{N-3} can be the same or different and are as defined above,

(22) - R_{N-4} where R_{N-4} is as defined above,

(23) - $O-CO-(C_1-C_6$ alkyl),

(24) - $O-CO-N(C_1-C_3$ alkyl)₂,

(25) - $O-CS-N(C_1-C_3$ alkyl)₂.

- (26) -O-(C₁-C₆ alkyl),
- (27) -O-(C₂-C₅ alkyl)-COCH₃,
- (28) -S-(C₁-C₆ alkyl),
- (29) C₁-C₆ alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F,
- (30) -O-(C₁-C₆ alkyl unsubstituted or substituted with 1, 2, 3, 4, or 5 -F, or
- (31) -O- ϕ ,

R_{n-1} is phenyl that is independently substituted with one, two, three or four of R₁₀₀;

R_a is hydrogen or C₁-C₆ alkyl;

R_c is

R_{cX} where R_{cX} is morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydrothiophenyl, each of which is optionally substituted with oxo, C₁-C₃ alkyl, -CF₃, -F, Cl, -Br or -I, C₁-C₃ alkoxy, -O-CF₃, -NH₂, -OH, or -C≡N;

R_{cY} where R_{cY} is pyridinyl, pyrimidinyl, quinolinyl, indenyl, indanyl, benzothiophenyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, ~~thalazinyl, indazolyl,~~ isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, 1, 4-benzodioxanyl, purinyl, oxazolopyridinyl, imidazopyridinyl, isothiazolyl, naphthyridinyl, cinnolinyl, carbazolyl, β -carbolinyl,

isochromanyl, chromanyl, furazanyl,
 tetrahydroisoquinoline, isoindolinyl,
 isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl,
 isobenzothiophenyl, benzoxazolyl, or pyridopyridinyl,
 each of which is optionally substituted with C_1 - C_3 alkyl,
 $-CF_3$, $-F$, Cl , $-Br$, or I , C_1 - C_3 alkoxy, $-O-CF_3$, $-NH_2$, $-OH$,
 or $-C\equiv N$;
 $-(C_1-C_{10})$ alkyl- R_{CH} ; or
 $-(C_1-C_{10})$ alkyl- R_{CH} .

Claim 189 (new) A compound according to claim 172, which
 is N -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-⁽¹⁸⁸⁾
 (piperidine-1-carbonyl)-hexyl]- N,N -dipropyl-isophthalamide.

Claim 190 (new) A compound according to claim 172, which
 is N -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-(2-⁽¹⁸⁸⁾
 morpholin-4-yl-ethylcarbamoyl)-pentyl]-5-methyl- N,N -dipropyl-
 isophthalamide.

Claim 191 (new) A compound according to claim 172, which
 is N -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-⁽¹⁸⁸⁾
 [(tetrahydro-furan-2-ylmethyl)-carbamoyl]-pentyl]-5-methyl- N,N -
 dipropyl-isophthalamide.

Claim 192 (new) A compound according to claim 172, which
 is N -[(1-(S)-(3,5-Difluoro-benzyl)-2-(S)-hydroxy-4-(R)-methyl-5-⁽¹⁸⁸⁾
 morpholin-4-yl-5-oxo-pentyl]-5-methyl- N,N -dipropyl-
 isophthalamide.

Claim 193 (new) A compound according to claim 172, which
 is N -[(1-(S)-(3,5-Difluoro-benzyl)-4-(R)-[(furan-2-ylmethyl)-⁽¹⁸⁸⁾

carbamoyl]-2-(S)-hydroxy-pentyl)-5-methyl-N,N-dipropyl-isophthalamide.

194. (new) A pharmaceutical composition comprising a compound according to claim 188 in combination with a pharmaceutically acceptable carrier.

A1
H1B2
21
10/6/04

195. (new) A method according of treating or preventing Alzheimer's Disease comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 188.